Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM0N634)

Drug Name
CITCO Drug Info
Synonyms
CITCO; 338404-52-7; UNII-D77H8321PB; 6-(4-CHLOROPHENYL)IMIDAZO[2,1-B][1,3]THIAZOLE-5-CARBALDEHYDE O-(3,4-DICHLOROBENZYL)OXIME; CHEMBL458603; D77H8321PB; 6-(4-Chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime; 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime; CITCO cpd; Spectrum5_001974; BSPBio_001028; SCHEMBL241281; DTXSID4040761; CHEBI:92928; BCBcMAP01_000217; 6-[4-Chlorophenyl]imidazo[2,1-b][1,3]thiazole-5-carbaldehydeo-[3,4-dichlorobenzyl]oxime
Cross-matching ID
PubChem CID
9600409
ChEBI ID
CHEMBL92928
CAS Number
CAS 338404-52-7
TTD Drug ID
D01BXE

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Mineral absorption 2.27 0.00e+0 48/60 (80%) MT1X;MT1G;MT1H;...
Porphyrin and chlorophyll metabolism 2.06 0.00e+0 23/43 (53.49%) HMBS;ALAS2;BLVRB;...
Drug metabolism 2.05 3.40e-3 78/151 (51.66%) CYP1A2;MAOB;GSTP1;...
Dilated cardiomyopathy 1.99 2.55e-3 86/96 (89.58%) TPM2;TNNC1;ACTC1;...
Steroid hormone biosynthesis 1.97 4.07e-3 43/61 (70.49%) HSD11B1;CYP1A2;CYP3A4;...
Hypertrophic cardiomyopathy 1.93 6.79e-3 81/90 (90%) TPM2;TNNC1;ACTC1;...
Cardiac muscle contraction 1.91 7.28e-3 64/87 (73.56%) TPM2;TNNC1;ACTC1;...
Retinol metabolism 1.90 7.64e-3 41/68 (60.29%) ALDH1A2;CYP1A2;CYP3A4;...
Graft-versus-host disease 1.80 1.81e-2 32/42 (76.19%) GZMB;PRF1;KLRD1;...
Glycolysis / Gluconeogenesis 1.79 1.83e-2 56/67 (83.58%) FBP1;PFKM;PGAM1;...
Valine, leucine and isoleucine degradation 1.78 2.13e-2 42/48 (87.5%) ACAT1;HMGCS2;AUH;...
Glucagon signaling pathway 1.75 2.21e-2 89/107 (83.18%) SLC2A1;PPP3CA;PLCB1;...
Glycine, serine and threonine metabolism 1.68 4.47e-2 31/40 (77.5%) ALAS2;GNMT;MAOB;...
TNF signaling pathway -1.80 4.25e-2 103/112 (91.96%) CREB5;JUNB;AKT2;...
NF-kappa B signaling pathway -1.93 0.00e+0 90/104 (86.54%) TRIM25;LY96;EDA;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 12uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H, 24H